Chong Kun Dang Pharmaceutical 185750.KS · KRW

Its shares trade on KRX under the ticker 185750.KS. It has been listed since 6 December 2013. In the fiscal year to 31 December 2025, it reported revenue of ₩1.69trn and net income of ₩77.51bn. At that date it held total assets of ₩1.80trn and shareholders' equity of ₩1.00trn.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jang Han LeeChairman
• Mr. Yeong Ju KimPresident, Director
• Ms. Chun Gyeong OhChief Technology Officer, Vice President
• Mr. Seong Gon KimManaging Director, Director
• Mr. Jong Rae YimManaging Director, Director
• Mr. Jang Won ChoiManaging Director
• Mr. Yun Han LeeManaging Director
• Mr. Ja Min GuOther, Director, since 2021
• Mr. Hong Bae KimInternal Auditor
• Gi Won KimDirector
• Mr. Sun Wuk HongNon-Executive Independent Director
• Mr. Yin Su KangNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.